TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7495248

Group type: EXPERIMENTAL
Intervention: Supplementation with beta-carotene, vitamin E, and selenium
Number of subjects: 30000

Group type: EXPERIMENTAL
Intervention: Daily supplementation with 14 vitamins and 12 minerals at two to three times the US RDA
Number of subjects: 30000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30000
Study: 1783363

Group type: EXPERIMENTAL
Intervention: Combination of amiloride (2 x 2.5 mg) and long‐acting furosemide (2 x 10 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Amiloride (5 mg) and furosemide (20 mg)
Number of subjects: 12
Study: 6813814

Group type: EXPERIMENTAL
Intervention: External pneumatic calf compression (EPCC)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: EPCC combined with aspirin (300 mg bid) and dipyridamole (75 mg tid)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Untreated patients (previous study)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Overall group (EPCC and ASA/dip)
Number of subjects: 28
Study: 31993943

Group type: EXPERIMENTAL
Intervention: Once-daily tacrolimus
Number of subjects: 242

Group type: COMPARATOR
Intervention: Twice-daily cyclosporine
Number of subjects: 242
Study: 31794625

Group type: EXPERIMENTAL
Intervention: Single-fraction 8-Gy radiotherapy (n=345)
Number of subjects: 686

Group type: COMPARATOR
Intervention: Multifraction 20 Gy in 5 fractions (n=341)
Number of subjects: 686

Group type: EXPERIMENTAL
Intervention: Single-fraction 8-Gy radiotherapy
Number of subjects: 686

Group type: COMPARATOR
Intervention: Multifraction 20 Gy in 5 fractions
Number of subjects: 686
Study: 28215837

Group type: EXPERIMENTAL
Intervention: Liquid sclerotherapy with Y connector (Group A)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Liquid sclerotherapy direct to cannula (Group B)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Foam sclerotherapy direct to cannula (Group C)
Number of subjects: 91

Group type: COMPARATOR
Intervention: Control group (Group A)
Number of subjects: 91
Study: 26360770

Group type: EXPERIMENTAL
Intervention: Endotoxin
Number of subjects: 115

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 115
Study: 24160570

Group type: EXPERIMENTAL
Intervention: Sm(avg) obtained by spectral pulse wave Tissue Doppler Imaging (pwTDI) from the lateral and septal sites of the mitral annulus.
Number of subjects: 313

Group type: COMPARATOR
Intervention: Simpson's rule for assessing EF.
Number of subjects: 313
Study: 21351127

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 50-300 U
Number of subjects: 313

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA ≥100 U
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 150, 200, and 300 U
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA >150 U
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA
Number of subjects: 313
Study: 19664568

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 15603

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15603

Group type: EXPERIMENTAL
Intervention: Withdrawers
Number of subjects: 15603
Study: 18183080

Group type: EXPERIMENTAL
Intervention: 90-minute alcohol health education session
Number of subjects: 71

Group type: COMPARATOR
Intervention: Health education regarding smoking
Number of subjects: 71
Study: 15085948

Group type: EXPERIMENTAL
Intervention: Community liaison pharmacy service intervention
Number of subjects: 162

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 162
Study: 11811547

Group type: EXPERIMENTAL
Intervention: Vitamin E (200 mg of D‐alpha‐tocopheryl acetate daily)
Number of subjects: 520

Group type: EXPERIMENTAL
Intervention: Vitamin C (500 mg of slow release ascorbate daily)
Number of subjects: 520

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 520
Study: 9515998

Group type: EXPERIMENTAL
Intervention: Reduced sodium intake
Number of subjects: 975

Group type: EXPERIMENTAL
Intervention: Weight loss
Number of subjects: 975

Group type: COMPARATOR
Intervention: Reduced sodium intake alone
Number of subjects: 975

Group type: COMPARATOR
Intervention: Weight loss alone
Number of subjects: 975

Group type: COMPARATOR
Intervention: Reduced sodium intake and weight loss combined
Number of subjects: 975

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 975
Study: 7775548

Group type: EXPERIMENTAL
Intervention: Combined perioperative infusion of nifedipine and metoprolol (NM)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Nifedipine only (N)
Number of subjects: 70
Study: 30125529

Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 360

Group type: COMPARATOR
Intervention: Sham electroacupuncture
Number of subjects: 360
Study: 27025986

Group type: EXPERIMENTAL
Intervention: Oxycodone ER (Xtampza ER)
Number of subjects: 193

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 193
Study: 24955456

Group type: EXPERIMENTAL
Intervention: Lamivudine
Number of subjects: 181

Group type: COMPARATOR
Intervention: Control
Number of subjects: 181
Study: 24301248

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05% spray (CPS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle spray
Number of subjects: 0
Study: 20950697

Group type: EXPERIMENTAL
Intervention: Start To Run program (10 weeks)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Sedentary control group
Number of subjects: 19
Study: 18335118

Group type: EXPERIMENTAL
Intervention: Topical application of 20 ml of honey before and after radiation therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Rinsing with 20 ml of saline before and after radiation therapy
Number of subjects: 40
Study: 17140970

Group type: EXPERIMENTAL
Intervention: 50 mg oral sildenafil
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 14698783

Group type: EXPERIMENTAL
Intervention: [(99m)Tc]DTPA-mannosyl-dextran (0.2 nmol)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: [(99m)Tc]DTPA-mannosyl-dextran (1.0 nmol)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: [(99m)Tc]DTPA-mannosyl-dextran (5.0 nmol)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Filtered [(99m)Tc]sulfur colloid
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: [(99m)Tc]DTPA-mannosyl-dextran (all doses)
Number of subjects: 24
Study: 10714909

Group type: EXPERIMENTAL
Intervention: 7-day-Estradiol patch (50 microg estradiol per day)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study: 9187443

Group type: EXPERIMENTAL
Intervention: Involved-field radiotherapy (IF-RT) given to 90% of patients in partial remission (PR) after chemotherapy.
Number of subjects: 493

Group type: COMPARATOR
Intervention: No further treatment for patients in complete remission (CR) after chemotherapy.
Number of subjects: 493
Study: 8235775

Group type: EXPERIMENTAL
Intervention: Flumazenil
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study: 3516622

Group type: EXPERIMENTAL
Intervention: Fructose (0.325 g/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Glucose (0.325 g/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control (water only)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Dark bread (2 BU) with butter and water
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fructose (1 BU substitution)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sorbitol (1 BU substitution)
Number of subjects: 12
Study: 31023318

Group type: EXPERIMENTAL
Intervention: Perioperative systemic therapy and CRS‐HIPEC
Number of subjects: 358

Group type: COMPARATOR
Intervention: Upfront CRS‐HIPEC alone
Number of subjects: 358
Study: 30095746

Group type: EXPERIMENTAL
Intervention: Early continuous positive airways pressure
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 42
Study: 27310943

Group type: EXPERIMENTAL
Intervention: Standard treatment for BDII for 12 weeks
Number of subjects: 117
Study: 25212646

Group type: EXPERIMENTAL
Intervention: Aspiration thrombectomy
Number of subjects: 440

Group type: COMPARATOR
Intervention: Standard PCI
Number of subjects: 440

Group type: EXPERIMENTAL
Intervention: Combined clinical endpoint
Number of subjects: 440
Study: 22033719

Group type: EXPERIMENTAL
Intervention: Iterative Reconstruction (IR) at 275 mAs (15% dose reduction)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Iterative Reconstruction (IR) at 225 mAs (30% dose reduction)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Filtered Back-Projection (FBP) at 320 mAs (standard dose)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Filtered Back-Projection (FBP) at 275 mAs (15% dose reduction)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Filtered Back-Projection (FBP) at 225 mAs (30% dose reduction)
Number of subjects: 90
Study: 20148254

Group type: COMPARATOR
Intervention: 25‐G Quincke type spinal needle
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: 29‐G Quincke type spinal needle
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Ambulatory patients
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Women
Number of subjects: 216
Study: 19338490

Group type: EXPERIMENTAL
Intervention: C2 levels in schistosomal group (511 ‐/+ 118 nmol/L)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: C2.5 levels in schistosomal group (730 ‐/+ 215 nmol/L)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: C2.5
Number of subjects: 100
Study: 15674316

Group type: EXPERIMENTAL
Intervention: Low-sodium group (LS)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 29
Study: 11907307

Group type: EXPERIMENTAL
Intervention: Active ligatures
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Powerchain
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Nickel-titanium springs
Number of subjects: 33
Study: 10550139

Group type: EXPERIMENTAL
Intervention: Presence of cytokeratin 18-positive cells in bone marrow
Number of subjects: 287

Group type: EXPERIMENTAL
Intervention: Preoperative detection of cells containing cytokeratin 18
Number of subjects: 287
Study: 8540794

Group type: EXPERIMENTAL
Intervention: Modular KAFOs
Number of subjects: 9

Group type: COMPARATOR
Intervention: Original KAFOs
Number of subjects: 9
Study: 2185452

Group type: EXPERIMENTAL
Intervention: Cefadroxil (1 gm, single-dose)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Erythromycin (base or stearate)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Erythromycin (high-dose, 1-day regimen)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Penicillin V
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control group (no peritreatment antibiotics)
Number of subjects: 200
Study: 381887

Group type: EXPERIMENTAL
Intervention: Daunorubicin 60 mg/M2 daily X 3, cytosine arabinoside and thioguanine 100 mg/M2 each every 12 hours until marrow hypoplasia achieved
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: 5-day course of daunorubicin 100 mg/M2 on day 1, cytosine arabinoside plus thioguanine 100 mg/M2 every 12 hours for five days
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: 6-mercaptopurine 100 mg/M2 daily
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: 6-thioguanine 100 mg/M2 daily
Number of subjects: 523

Group type: EXPERIMENTAL
Intervention: 50 mg/M2 of both 6-mercaptopurine and 6-thioguanine daily
Number of subjects: 523
Study: 31878810

Group type: EXPERIMENTAL
Intervention: hEGH gel (Regen-D 150)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 50
Study: 30836366

Group type: EXPERIMENTAL
Intervention: 1-day PEG-3350 with bisacodyl (PEG-B)
Number of subjects: 124

Group type: COMPARATOR
Intervention: 3-day sennosides
Number of subjects: 124
Study: 29201144

Group type: EXPERIMENTAL
Intervention: Interspinous Dynamic Stabilization System (IDSS)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Posterior Lumbar Interbody Fusion (PLIF)
Number of subjects: 67
Study: 25657075

Group type: EXPERIMENTAL
Intervention: Neutral positioning (LiN)
Number of subjects: 218

Group type: COMPARATOR
Intervention: Conventional positioning (CON)
Number of subjects: 218
Study: 24227660

Group type: EXPERIMENTAL
Intervention: Canagliflozin 50 mg
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Canagliflozin 300 mg
Number of subjects: 376

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 376
Study: 23055513

Group type: EXPERIMENTAL
Intervention: Early visual cortex responses to varying stimulation rates
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Middle- and higher-tier regions of the ventral visual stream
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Attention during incidental task
Number of subjects: 0
Study: 19357528

Group type: EXPERIMENTAL
Intervention: Lamotrigine (236+/‐150 mg/day)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 17855483

Group type: EXPERIMENTAL
Intervention: BQ-788 (ETB receptor blockade)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: BQ-788 and BQ-123 (combined ET receptor blockade)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: COMPARATOR
Intervention: BQ-123 (ETA receptor blockade)
Number of subjects: 16
Study: 15881863

Group type: EXPERIMENTAL
Intervention: New Livfit (NLF)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 12030661

Group type: EXPERIMENTAL
Intervention: Angina Plan (cognitive behavioural disease management programme)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Routine practice nurse‐led secondary prevention educational session
Number of subjects: 142
Study: 9583767

Group type: EXPERIMENTAL
Intervention: Placebo analgesia after buprenorphine treatment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Placebo respiratory depression after buprenorphine treatment
Number of subjects: 0
Study: 7662835

Group type: EXPERIMENTAL
Intervention: Antianginal drug
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 2128879

Group type: EXPERIMENTAL
Intervention: Daily injections or pulsatile subcutaneous administration of human menopausal gonadotropin (hMG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of clomiphene citrate and bromocriptine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of clomiphene citrate and hMG
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Various clinical conditions and types of preparations administered
Number of subjects: 0
Study: 533574

Group type: EXPERIMENTAL
Intervention: Oral antipyrine treatment over 4 or 5 weeks in vegetarian Asians and non-vegetarians
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Oral antipyrine treatment
Number of subjects: 44

Group type: COMPARATOR
Intervention: Caucasian non-vegetarian group
Number of subjects: 44
Study: 30148161

Group type: EXPERIMENTAL
Intervention: Polyherbal formulation (PHF) 750 mg/d in three doses for 90 days
Number of subjects: 36
Study: 27038769

Group type: EXPERIMENTAL
Intervention: OnabotulinumtoxinA 100 U
Number of subjects: 0
Study: 24106334

Group type: EXPERIMENTAL
Intervention: Clonidine 25 µg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Clonidine 50 µg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Clonidine 75 µg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Clonidine 150 µg
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 22920408

Group type: EXPERIMENTAL
Intervention: Brief Advice and referral for Brief Intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Leaflet on healthy living (Control)
Number of subjects: 0
Study: 20386480

Group type: EXPERIMENTAL
Intervention: Static stretching
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Ballistic stretching
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: No stretching
Number of subjects: 25
Study: 17296323

Group type: COMPARATOR
Intervention: Patellar taping
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (no taping)
Number of subjects: 32
Study: 16265778

Group type: EXPERIMENTAL
Intervention: 3-IP (omega-3 fatty acid, 3 g/day)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: 6-IP (omega-6 fatty acid, 9 g/day)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control (prednisolone 40 mg for 1 week, tapering by 5 mg/week)
Number of subjects: 31
Study: 12053586

Group type: EXPERIMENTAL
Intervention: CAST‐ELISA test with unconjugated penicillin
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: CAST‐ELISA test with penicillin‐polylysine
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: CAST‐ELISA test with penicillin conjugated to human serum albumin
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: CAST‐ELISA test (overall)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (healthy persons)
Number of subjects: 46
Study: 10814677

Group type: EXPERIMENTAL
Intervention: Hybrid Capture II (HCII) assay
Number of subjects: 2944

Group type: EXPERIMENTAL
Intervention: Hybrid Capture I (HCI) assay
Number of subjects: 2944

Group type: COMPARATOR
Intervention: Cytology
Number of subjects: 2944

Group type: EXPERIMENTAL
Intervention: HPV DNA testing (HCII)
Number of subjects: 2944

Group type: EXPERIMENTAL
Intervention: HPV DNA testing
Number of subjects: 2944
Study: 8634560

Group type: EXPERIMENTAL
Intervention: Albendazole 800 mg twice daily for two weeks
Number of subjects: 174

Group type: EXPERIMENTAL
Intervention: Albendazole
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study: 2054264

Group type: EXPERIMENTAL
Intervention: Ferrous sulphate (300 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Ferrous gluconate (600 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Centrum Forte (combination tablet)
Number of subjects: 8
Study: 6094434

Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 68

Group type: COMPARATOR
Intervention: Penicillin-gentamicin
Number of subjects: 68
Study: 31370976

Group type: EXPERIMENTAL
Intervention: Usual dose of buprenorphine (100%)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 150% of usual daily dose of buprenorphine
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 200% of usual daily dose of buprenorphine
Number of subjects: 7
Study: 29499728

Group type: EXPERIMENTAL
Intervention: Osteopathic visceral manipulation (OVM) for 15 min once per week for six weeks
Number of subjects: 76

Group type: COMPARATOR
Intervention: Sham osteopathic visceral manipulation (SOVM) once per week for six weeks
Number of subjects: 76
Study: 27278054

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 44
Study: 26117356

Group type: EXPERIMENTAL
Intervention: rTMS
Number of subjects: 15
Study: 22261849

Group type: EXPERIMENTAL
Intervention: Endoscopic CO(2) laser resections combined with mitomycin‐C and/or triamcinolone acetonide therapy
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Long‐term oral steroid and immunosuppressive therapy as well as the use of proton pump inhibitors
Number of subjects: 11
Study: 19622596

Group type: COMPARATOR
Intervention: XELOX(30)
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: XELOX(30Chron)
Number of subjects: 141
Study: 18614936

Group type: EXPERIMENTAL
Intervention: 2 min passive stretching (PS2)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 4 min passive stretching (PS4)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: 8 min passive stretching (PS8)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (CON) with no stretching
Number of subjects: 13
Study: 15854235

Group type: EXPERIMENTAL
Intervention: Endovascular coiling
Number of subjects: 62

Group type: COMPARATOR
Intervention: Neurosurgical clipping
Number of subjects: 62
Study: 11815507

Group type: EXPERIMENTAL
Intervention: Repaglinide taken before each of the three main meals
Number of subjects: 19

Group type: COMPARATOR
Intervention: Repaglinide taken before breakfast and before the evening meal
Number of subjects: 19
Study: 10401941

Group type: EXPERIMENTAL
Intervention: Dexamethasone (10 mg q.i.d. for 3 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 7722951

Group type: EXPERIMENTAL
Intervention: Forced-air warming (Warm Touch, Mallinckrodt Medical, Inc, St Louis, MO)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Routine thermal care
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Forced-air warming
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Body temperature measurement sites (bladder, oral cavity, rectum, tympanic membrane)
Number of subjects: 29
Study: 2327747

Group type: EXPERIMENTAL
Intervention: Piperacillin (4 g every 12 h for four doses) with Tobramycin (2 mg/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Piperacillin (4 g every 12 h for four doses) with Netilmicin (2 mg/kg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Piperacillin (4 g single dose)
Number of subjects: 12
Study: 6353840

Group type: EXPERIMENTAL
Intervention: Bupivacaine without adrenaline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bupivacaine with adrenaline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chloroprocaine without adrenaline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chloroprocaine with adrenaline
Number of subjects: 0
Study: 31362773

Group type: EXPERIMENTAL
Intervention: Low-carbohydrate/high-protein (LC/HP) dietary intervention (30% total energy as protein, 1.6 g/kg per day, carbohydrate-to-protein ratio < 1.5, fat intake at 30% of total energy)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no dietary intervention, regular daily diets)
Number of subjects: 100
Study: 29937536

Group type: EXPERIMENTAL
Intervention: Enteric tablets with high-protein meal
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Non-enteric tablets
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Garlic powder capsules
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Kwai garlic powder tablets
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Cooked garlic foods (boiled)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Cooked garlic foods (roasted)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Cooked garlic foods (pickled)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Cooked garlic foods (acid-minced)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Black garlic
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control (homogenized raw garlic)
Number of subjects: 13
Study: 26632655

Group type: EXPERIMENTAL
Intervention: Laparoscopic nerve-sparing radical hysterectomy (LNRH)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Laparoscopic radical hysterectomy (LRH)
Number of subjects: 120